Pricing Log in Create free account

Grace Therapeutics, Inc. (GRCE) vs Pelthos Therapeutics Inc. (PTHS)

Grace Therapeutics, Inc. and Pelthos Therapeutics Inc. are both Biotechnology companies. Grace Therapeutics, Inc. and Pelthos Therapeutics Inc. are of similar size ($37.5M and $35.6M). Grace Therapeutics, Inc. has the higher net margin (0.00% vs −199.5%) and the higher return on invested capital (−43.4% vs −82.3%). Across the 15 metrics below, Grace Therapeutics, Inc. leads on 9 and Pelthos Therapeutics Inc. on 6.

Valuation

Metric GRCE PTHS Biotechnology median
P/E n/m n/m 10.60
P/S 160.85 0.78 9.40
P/B 0.67 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 106.08 1.88 9.02
Earnings yield (63.44%) (276.23%) (32.88%)
Free cash flow yield (31.78%) (126.55%) (23.13%)

Profitability

Metric GRCE PTHS Biotechnology median
Gross margin 0.00% 78.59% 68.51%
Operating margin 0.00% (133.42%) 0.00%
Net margin 0.00% (199.50%) 0.00%
Free cash flow margin 0.00% (98.37%) 0.00%
Return on equity (36.19%) 2,161.07% (51.96%)
Return on assets (33.74%) (125.04%) (46.06%)
Return on invested capital (43.36%) (82.34%) 0.00%

Growth

Metric GRCE PTHS Biotechnology median
Revenue growth (TTM) 1,286.81% — 6.76%
EPS growth (last fiscal year) 40.51% (61.12%) 29.88%
Revenue growth, 5-year CAGR (22.91%) — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric GRCE PTHS Biotechnology median
Debt to equity 0.00 (46.58) 0.00
Current ratio 11.47 1.98 4.97
Net debt to EBITDA 1.53 (0.45) 1.01

Dividend

Metric GRCE PTHS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GRCE PTHS Biotechnology median
Market cap 37.45m 35.61m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack